GCIBofA Merrill Lynch lifts Smith & Nephew price target
(Sharecast News) - Bank of America Merrill Lynch upped its price target on Smith & Nephew Plc (SN.) on Wednesday to 1,320p from 1,180p.
Despite the share price recovery of around 20% since October's 10-year low, the bank thinks Smith & Nephew remains one of the few value opportunities in EU MedTech, with potential upside since the share price remains around 10% below the Covid trough.
"While the Orthopaedics challenges have been a big overhang for the equity story, we are now seeing some light at the end of the tunnel: Supply chain has improved, and efforts are focused on sales reps' efficiency," it said.
"As we start to see normalisation, we look at several opportunities for Ortho. CORI robot, cementless mix shift and the AETOS shoulder could all contribute materially to group sales and profits."
Finally, BofA said its reverse sum-of-the-parts suggests no value for the Ortho business in S&N's current market value, which it reckons is unfair.
The bank maintained its 'buy' rating on the stock.
At 1245 GMT, the shares were up 1.9% at 1,085p.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.